Neurogene Inc. Payments of Loan Costs
Neurogene Inc. (NGNE) reported Payments of Loan Costs of $100.00 thousand for the 12-month period ending 2014-12-31, per its 10-K filed 2015-03-16.
Discontinued › Cash Flow › Financing Activities
us-gaap:PaymentsOfLoanCosts · last filed 2015-03-16
- Neurogene Inc. payments of loan costs for fiscal 2014 was $100.00K, a 7.08% decline from fiscal 2013.
- Neurogene Inc. payments of loan costs for fiscal 2013 was $107.62K.
| Period end | Payments of Loan Costs 12 month | Payments of Loan Costs 123 month |
|---|---|---|
| 2014-12-31 | $100.00K 10-K · filed 2015-03-16 | |
| 2014-03-31 | $107.91K 10-Q · filed 2014-05-13 | |
| 2013-12-31 | $107.62K 10-K · filed 2015-03-16 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Shattuck Labs, Inc. (STTK) | United States | $0.634B | -13.30 |
| IMPACT BIOMEDICAL INC. (IBO) | United States | $0.611B | 66.47 |
| Aquestive Therapeutics, Inc. (AQST) | United States | $0.606B | -6.67 |
| CorMedix Inc. (CRMD) | United States | $0.605B | 3.25 |
| BlossomHill Therapeutics, Inc. (BLSM) | United States | $0.647B | |
| CytomX Therapeutics, Inc. (CTMX) | United States | $0.598B | -10.25 |
| Monopar Therapeutics (MNPR) | United States | $0.598B | -34.82 |
| Altimmune, Inc. (ALT) | United States | $0.593B | -6.43 |
| ZEVRA THERAPEUTICS, INC. (ZVRA) | United States | $0.668B | 14.61 |
| Phathom Pharmaceuticals, Inc. (PHAT) | United States | $0.572B | -8.76 |